Three Companies Combine for One Goal

June 22, 2009

Company News Release

Research Triangle Park, NC - June 22, 2009: PharmaLinkFHI announced today they have officially changed their name to Novella Clinical. Global growth through the 2008 acquisition of Matrix Clinical in the U.K. made the name change necessary.

The announcement was made simultaneously at their global headquarters in Research Triangle Park, as well as at their European office in Stevenage U.K. and at the Drug Information Association's (DIA) annual conference - one of the most significant events in the industry.

"The combination of PharmaLink and Matrix was an important event in the history of the company. It has allowed us to support our biopharmaceutical and medical device clients globally in their efforts to bring promising products to market. Our focus on leveraging clinical and therapeutic expertise with industry leading eClinical processes and technologies allows us to manage our business more effectively and provide superior clinical trial execution for our sponsors, now on a global scale" said Richard Staub, President and Chief Executive Officer.

Nigel Trim, Managing Director, European Operations, added, "As Novella Clinical we are poised to continue our growth globally - both within our current geographic footprint as well as expanding into new regions of the world. We are excited to reintroduce ourselves to the market as Novella Clinical."

Novella provides their clients with full-service CRO support through its biopharmaceutical and medical device divisions. Both divisions are built from teams of therapeutically trained professionals using industry-leading eClinical processes. For clients who don't require full-service CRO support, Novella Clinical Resourcing (formerly known as eReady Monitors and Matrix Clinical Solutions) offers flexible staffing solutions to supplement their clinical teams with unparalleled expertise.

In addition to the new name and rebranding efforts, Novella Clinical is rolling out a new line of communications to further differentiate themselves in the CRO marketplace. The communications are based on the company's brand promise of helping their clients achieve their goal of positively improving people's lives. That promise is further exemplified in their new tagline, "Moving Potential. Forward."

About Novella Clinical
For over a decade, Novella Clinical has been supporting biopharmaceutical companies with Phase I through post-marketing programs and medical device clients with Class II and III device programs. Although our clinical experience is all-inclusive, our eClinical roots enable us to offer services that are specific to our clients' needs, eliminating the demand to contract with multiple partners. From protocol development through final clinical study report ? we integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. Our focus on quality customer service is reflected in our certification by Underwriters Laboratories on meeting global quality standards (ISO 9001:2008). For more information, visit www.novellaclinical.com.

Related Content:

News